These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 32653388)

  • 1. Factors predicting outcomes of hepatitis B-related cirrhosis patients with long-term antiviral therapy.
    Lin CL; Tseng KC; Chen KY; Liao LY; Kao JH
    J Formos Med Assoc; 2020 Oct; 119(10):1483-1489. PubMed ID: 32653388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liver transplantation for hepatitis B virus: Decreasing indication and changing trends.
    Al-Hamoudi W; Elsiesy H; Bendahmash A; Al-Masri N; Ali S; Allam N; Al Sofayan M; Al Bahili H; Al Sebayel M; Broering D; Saab S; Abaalkhail F
    World J Gastroenterol; 2015 Jul; 21(26):8140-7. PubMed ID: 26185387
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Risk factors for the development of liver cancer in patients with hepatitis B-related liver cirrhosis treated with long-term nucleos(t)ide analogues].
    Zang WW; Su MH; Ling XZ; Wang RM; Cao BC; Wu YL; Deng DL; Wei HL; Liang XS; Jiang JN
    Zhonghua Gan Zang Bing Za Zhi; 2020 Aug; 28(8):679-685. PubMed ID: 32911907
    [No Abstract]   [Full Text] [Related]  

  • 4. Long-term prognosis with or without nucleot(s)ide analogue therapy in hepatitis B virus-related decompensated cirrhosis.
    Kumada T; Toyoda H; Yasuda S; Miyake N; Ito T; Tanaka J
    J Viral Hepat; 2021 Mar; 28(3):508-516. PubMed ID: 33306854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The clinical effect of antiviral therapy in patients with hepatitis B virus-related decompensated cirrhosis and undetectable DNA.
    Lee HA; Lee YS; Jung YK; Kim JH; Yim HJ; Yeon JE; Seo YS; Lee JS; Lee HW; Kim BK; Park JY; Kim DY; Ahn SH; Kim SU
    J Gastroenterol Hepatol; 2023 May; 38(5):716-723. PubMed ID: 36681856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of telbivudine efficacy in treatment-naive patients with hepatitis B virus-related compensated and decompensated cirrhosis in 96 weeks.
    Yang X; Li J; Zhou L; Liu J; Wang J; Lu W
    Eur J Gastroenterol Hepatol; 2014 Apr; 26(4):396-403. PubMed ID: 24569820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiviral drug resistance increases hepatocellular carcinoma: a prospective decompensated cirrhosis cohort study.
    Li L; Liu W; Chen YH; Fan CL; Dong PL; Wei FL; Li B; Chen DX; Ding HG
    World J Gastroenterol; 2013 Dec; 19(45):8373-81. PubMed ID: 24363530
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of virological response to entecavir on the development of hepatocellular carcinoma in hepatitis B viral cirrhotic patients: comparison between compensated and decompensated cirrhosis.
    Kim SS; Hwang JC; Lim SG; Ahn SJ; Cheong JY; Cho SW
    Am J Gastroenterol; 2014 Aug; 109(8):1223-33. PubMed ID: 24890440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis Flares Are Associated With Better Outcomes Than No Flare in Patients With Decompensated Cirrhosis and Chronic Hepatitis B Virus Infection.
    Chang ML; Cheng JS; Chien RN; Liaw YF
    Clin Gastroenterol Hepatol; 2020 Aug; 18(9):2064-2072.e2. PubMed ID: 31982607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Entecavir and Low Genetic Barrier Antiviral Agents for Hepatocellular Carcinoma in Hepatitis B Viral Cirrhosis: Propensity Score Matching.
    Li T; Qu Y; Wang Y; Lin C; Yang B; Wang L
    J Coll Physicians Surg Pak; 2019 Apr; 29(4):317-323. PubMed ID: 30925952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients.
    Su TH; Hu TH; Chen CY; Huang YH; Chuang WL; Lin CC; Wang CC; Su WW; Chen MY; Peng CY; Chien RN; Huang YW; Wang HY; Lin CL; Yang SS; Chen TM; Mo LR; Hsu SJ; Tseng KC; Hsieh TY; Suk FM; Hu CT; Bair MJ; Liang CC; Lei YC; Tseng TC; Chen CL; Kao JH;
    Liver Int; 2016 Dec; 36(12):1755-1764. PubMed ID: 27634134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence of hepatocellular carcinoma in chronic hepatitis B virus infection in those not meeting criteria for antiviral therapy.
    Alshuwaykh O; Daugherty T; Cheung A; Goel A; Dhanasekaran R; Ghaziani TT; Ahmed A; Dronamraju D; Kumari R; Kwong A; Nguyen M; Kim WR; Kwo PY
    Hepatol Commun; 2022 Nov; 6(11):3052-3061. PubMed ID: 36004713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognosis of hepatitis B-related liver cirrhosis in the era of oral nucleos(t)ide analog antiviral agents.
    Kim CH; Um SH; Seo YS; Jung JY; Kim JD; Yim HJ; Keum B; Kim YS; Jeen YT; Lee HS; Chun HJ; Kim CD; Ryu HS
    J Gastroenterol Hepatol; 2012 Oct; 27(10):1589-95. PubMed ID: 22554121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Forty-eight-week retrospective study of telbivudine and lamivudine treatment in patients with hepatitis B-related cirrhosis.
    Han Z; Shi Y; Zhu J; Chen Y; Yin F; Xia L; Luo G; Gao Z; Liu J; Jia G; Li C; Zhou X; Han Y
    J Viral Hepat; 2013 Apr; 20 Suppl 1():58-64. PubMed ID: 23458526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long term outcome of antiviral therapy in patients with hepatitis B associated decompensated cirrhosis.
    Ju YC; Jun DW; Choi J; Saeed WK; Lee HY; Oh HW
    World J Gastroenterol; 2018 Oct; 24(40):4606-4614. PubMed ID: 30386110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of entecavir in treatment-naïve patients with hepatitis B virus-related decompensated cirrhosis.
    Shim JH; Lee HC; Kim KM; Lim YS; Chung YH; Lee YS; Suh DJ
    J Hepatol; 2010 Feb; 52(2):176-82. PubMed ID: 20006394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study.
    Papatheodoridis GV; Manolakopoulos S; Touloumi G; Vourli G; Raptopoulou-Gigi M; Vafiadis-Zoumbouli I; Vasiliadis T; Mimidis K; Gogos C; Ketikoglou I; Manesis EK;
    Gut; 2011 Aug; 60(8):1109-16. PubMed ID: 21270118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical features and outcomes of hepatocellular carcinoma in Caucasian cirrhotic patients on long-term analogue therapy for hepatitis B.
    Loglio A; Iavarone M; Grossi G; Viganò M; Rumi MG; Facchetti F; Lunghi G; Sangiovanni A; Colombo M; Lampertico P
    Aliment Pharmacol Ther; 2018 Aug; 48(4):431-439. PubMed ID: 29920698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The long-term benefits of nucleos(t)ide analogs in compensated HBV cirrhotic patients with no or small esophageal varices: A 12-year prospective cohort study.
    Lampertico P; Invernizzi F; Viganò M; Loglio A; Mangia G; Facchetti F; Primignani M; Jovani M; Iavarone M; Fraquelli M; Casazza G; de Franchis R; Colombo M
    J Hepatol; 2015 Nov; 63(5):1118-25. PubMed ID: 26100495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of Virologic Response to Treatment on Short- and Long-term Outcomes of Patients With Chronic Hepatitis B Virus Infection and Decompensated Cirrhosis.
    Jang JW; Choi JY; Kim YS; Yoo JJ; Woo HY; Choi SK; Jun CH; Lee CH; Sohn JH; Tak WY; Lee YR; Han KH
    Clin Gastroenterol Hepatol; 2018 Dec; 16(12):1954-1963.e3. PubMed ID: 29753085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.